Identify functional chimeric antigen receptors three months faster with Alloy’s end-to-end CAR discovery
Webinar overview:
Looking for a way to accelerate your CAR-T therapeutic development projects? This presentation highlights how Alloy’s comprehensive platform and expertise can enable you to:
- Streamline end-to-end CAR discovery: Learn how Alloy’s full stack technologies enable discovery and screening of functional CARs with unprecedented speed and cost efficiency, overcoming limitations of conventional two-step processes.
- Drive success with case-validated approaches: Explore real-world applications including a highly specific TCRm CAR-T against
WT1/HLA-A2 and single domain antibodies against mesothelin, both demonstrating potent in vitro and in vivo efficacy. - Access integrated capabilities for complex targets: Discover how Alloy’s tailored workflows with fully integrated capabilities are designed to enable even the most difficult CAR discovery projects, from antibody generation to functional validation.
Webinar sample above. To access the full video content, fill out the form below.
If you’d like to access the recording from our recent webinar end-to-end CAR Discovery Platform: Accelerating CAR-T development–please submit your contact information. You will receive an email shortly with the recording link and a password.
About the Speaker:
Dongxing Zha, PhD
CTO, TCR Discovery & Engineering
Founder & CEO of Keyway TCR Discovery
Alloy Therapeutics
Dr. Dongxing Zha is the CEO of Keyway TCR Discovery at Alloy Therapeutics and is a seasoned drug development leader dedicated to the translation of immune-oncology discoveries into innovative anti-cancer therapies. Previously at MD Anderson Cancer Center, he oversaw a team that advanced the first TCRm to the clinic for treatment of various malignancies and was the leader of Oncology Research for Biologics and Immunotherapy Translation (ORBIT), a platform which develops biologic and cell-based therapies. Prior to that he served as a Research Fellow and Group Leader at Merck and a Senior Research Scientist at GlycoFi. Dr. Zha received his PhD in microbiology from Huazhong Agricultural University.
About the Speaker:
William “Beau” Carson IV, PhD
Senior Director, Immunology
Stealth Biotech Startup
Dr. William “Beau” Carson is the Senior Director of Immunology at a stealth-stage biotech startup. Prior to his current role, Dr. Carson was previously the Senior Director, Head of Translational Research at Alloy Therapeutics, where he oversaw the preclinical research team for vetting both in vitro and in vivo functional activity of antibody and cell-based modalities in a broad range of disease indications. Dr. Carson is a passionate immunologist with extensive experience in the complexities of immune response. He was previously a Principal Scientist and Senior Manager at Compass Therapeutics after serving as a Research Assistant Professor at the University of Michigan Medical School. Dr. Carson received his PhD in biomedical science-immunology from the University of Connecticut Health Center and worked as a Post Doctoral Fellow at the University of Michigan Medical School.